{"product_id":"immunology-for-life-scientists-paperback-softback-9780470845240","title":"Immunology for Life Scientists (Paperback \/ softback) 9780470845240","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eImmunology for Life Scientists\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eLesley-Jane Eales (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470845240, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback \/ softback, published 28 May 2003\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e368 pages\u003cbr\u003e24.5 x 16.8 x 2.1 cm, 0.794 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\"Immunology for Biomedical Scientists\" - Jetzt erscheint das beliebte Lehrbuch in der 2. umfassend überarbeiteten und aktualisierten Auflage.\u003cbr\u003e \u003cbr\u003e Es bietet eine Einführung in die Grundlagen der Immunologie und behandelt die wichtigsten Aspekte der Immunologie aussergewöhnlich fundiert und detailliert.\u003cbr\u003e \u003cbr\u003e Vorkenntnisse in Immunologie sind nicht erforderlich!\u003cbr\u003e \u003cbr\u003e Der Stoff wird Schritt für Schritt vermittelt.\u003cbr\u003e \u003cbr\u003e So gibt es z.B. umfassende Informationen zu Themen wie Antigene, Hypersensibilität, Autoimmunität, Reproduktionsimmunologie, und Immundefizienz.\u003cbr\u003e \u003cbr\u003e Mit zwei komplett neuen Kapiteln zur Interaktion von Immunsystem und extrazellulärer Matrix und zur Neuroimmunologie.\u003cbr\u003e \u003cbr\u003e Mit begleitender Website. Sie enthält Zusatzmaterial zum Selbsttest, CD-Marker\/Zytokin-Tabellen, Animationen schwieriger Konzepte sowie Farbabbildungen.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cb\u003ePreface.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003ePreface to the 1st Edition.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGlossary.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Cells and tissues of the immune system.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Cells involved in the immune response.\u003c\/p\u003e \u003cp\u003e1.1.1 Cellular origins – the pluripotent stem cell.\u003c\/p\u003e \u003cp\u003e1.1.2 Cells principally involved in the innate immune response.\u003c\/p\u003e \u003cp\u003ePolymorphonuclear leukocytes.\u003c\/p\u003e \u003cp\u003eNeutrophils.\u003c\/p\u003e \u003cp\u003eEosinophils.\u003c\/p\u003e \u003cp\u003eBasophils and mast cells.\u003c\/p\u003e \u003cp\u003eMegakaryocytes and platelets.\u003c\/p\u003e \u003cp\u003e1.1.3 Antigen presenting cells and large granular lymphocytes.\u003c\/p\u003e \u003cp\u003eMonocytes and macrophages.\u003c\/p\u003e \u003cp\u003eDendritic cells.\u003c\/p\u003e \u003cp\u003eLarge granular lymphocytes.\u003c\/p\u003e \u003cp\u003e1.1.4 Cells involved in the specific immune response.\u003c\/p\u003e \u003cp\u003eLymphocytes.\u003c\/p\u003e \u003cp\u003eT cells.\u003c\/p\u003e \u003cp\u003eB cells.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e1.2 Lymphoid tissues.\u003c\/p\u003e \u003cp\u003e1.2.1 Primary lymphoid tissues.\u003c\/p\u003e \u003cp\u003eThe thymus.\u003c\/p\u003e \u003cp\u003eMammalian \"bursa equivalents\".\u003c\/p\u003e \u003cp\u003eB cell development in the bone marrow.\u003c\/p\u003e \u003cp\u003e1.2.2 Secondary lymphoid tissues.\u003c\/p\u003e \u003cp\u003eThe lymphatic system.\u003c\/p\u003e \u003cp\u003eLymph nodes.\u003c\/p\u003e \u003cp\u003eSpleen.\u003c\/p\u003e \u003cp\u003e1.2.3 Tertiary lymphoid tissues.\u003c\/p\u003e \u003cp\u003eMucosa-associated lymphoid tissue.\u003c\/p\u003e \u003cp\u003eIntraepithelial lymphocytes.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Antigens and their receptors.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Characteristics of antigens and immunogens.\u003c\/p\u003e \u003cp\u003e2.1.1 Factors affecting immunogenicity.\u003c\/p\u003e \u003cp\u003eForeignness.\u003c\/p\u003e \u003cp\u003eSize.\u003c\/p\u003e \u003cp\u003eChemical complexity.\u003c\/p\u003e \u003cp\u003eRoute of administration.\u003c\/p\u003e \u003cp\u003eDose.\u003c\/p\u003e \u003cp\u003eHost genetic make-up.\u003c\/p\u003e \u003cp\u003eApproaches used to increase immunogenicity.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e2.2 The major histocompatibility factor.\u003c\/p\u003e \u003cp\u003e2.2.1 Class I MHC molecules.\u003c\/p\u003e \u003cp\u003e2.2.2 Class II MHC molecules.\u003c\/p\u003e \u003cp\u003e2.2.3 Non-classical HLA molecules.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e2.3 Antigen receptors on cells.\u003c\/p\u003e \u003cp\u003e2.3.1 The B cell antigen receptor.\u003c\/p\u003e \u003cp\u003eImmunoglobulins.\u003c\/p\u003e \u003cp\u003eAntibody structure.\u003c\/p\u003e \u003cp\u003eIsotypes.\u003c\/p\u003e \u003cp\u003eAllotypes.\u003c\/p\u003e \u003cp\u003eIdiotypes.\u003c\/p\u003e \u003cp\u003e2.3.2 Antibody classes.\u003c\/p\u003e \u003cp\u003eImmunoglobulin G.\u003c\/p\u003e \u003cp\u003eImmunoglobulin M.\u003c\/p\u003e \u003cp\u003eImmunoglobulin A.\u003c\/p\u003e \u003cp\u003eImmunoglobulin D.\u003c\/p\u003e \u003cp\u003eImmunoglobulin E.\u003c\/p\u003e \u003cp\u003e2.3.3 Antibody function.\u003c\/p\u003e \u003cp\u003e2.3.4 Fc receptors.\u003c\/p\u003e \u003cp\u003e2.3.5 The T cell antigen receptor.\u003c\/p\u003e \u003cp\u003eg d T cells.\u003c\/p\u003e \u003cp\u003eThe CD3 complex.\u003c\/p\u003e \u003cp\u003eFunction of the TCR–CD3 complex.\u003c\/p\u003e \u003cp\u003e2.3.6 The natural killer cell receptor.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e2.4 Generation of antigen receptor diversity.\u003c\/p\u003e \u003cp\u003e2.4.1 Theories concerning antibody diversity.\u003c\/p\u003e \u003cp\u003e2.4.2 The genetic basis of antibody diversity\u003c\/p\u003e \u003cp\u003eV, D and J region heavy chain genes.\u003c\/p\u003e \u003cp\u003eThe light chain V and J genes.\u003c\/p\u003e \u003cp\u003e2.4.3 Generation of antibody diversity.\u003c\/p\u003e \u003cp\u003eCombinatorial and junctional diversity.\u003c\/p\u003e \u003cp\u003eControl of VDJ gene rearrangement.\u003c\/p\u003e \u003cp\u003eMechanisms of V(D)J rearrangement.\u003c\/p\u003e \u003cp\u003eDiversity due to somatic mutation.\u003c\/p\u003e \u003cp\u003e2.4.4 Antibody maturation.\u003c\/p\u003e \u003cp\u003e2.4.5 Genetic basis of T cell antigen receptor diversity.\u003c\/p\u003e \u003cp\u003e\"Similarity to self rule\" – limited diversity.\u003c\/p\u003e \u003cp\u003eDiverse TCR repertoire.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRa chain.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRb chain.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRg chain.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRd chain.\u003c\/p\u003e \u003cp\u003e2.4.6 Generation of T cell antigen receptor diversity.\u003c\/p\u003e \u003cp\u003eSize of the T cell repertoire.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 The innate immune response.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 The complement cascades.\u003c\/p\u003e \u003cp\u003e3.1.1 The classical complement pathway.\u003c\/p\u003e \u003cp\u003eC1.\u003c\/p\u003e \u003cp\u003eC4.\u003c\/p\u003e \u003cp\u003eC2.\u003c\/p\u003e \u003cp\u003eC3.\u003c\/p\u003e \u003cp\u003e3.1.2 The alternative complement pathway.\u003c\/p\u003e \u003cp\u003e3.1.3 The lectin pathway.\u003c\/p\u003e \u003cp\u003e3.1.4 The membrane attack complex.\u003c\/p\u003e \u003cp\u003e3.1.5 Regulation of complement activation.\u003c\/p\u003e \u003cp\u003eC1 inhibitor (C1INH).\u003c\/p\u003e \u003cp\u003eRegulators of complement activation (RCA) family.\u003c\/p\u003e \u003cp\u003eRegulators of the membrane attack complex.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e3.2 Phagocytosis.\u003c\/p\u003e \u003cp\u003e3.2.1 Pattern recognition receptors.\u003c\/p\u003e \u003cp\u003eComplement receptor 3 (CR3).\u003c\/p\u003e \u003cp\u003eCD14.\u003c\/p\u003e \u003cp\u003eToll-like receptors.\u003c\/p\u003e \u003cp\u003eMacrophage scavenger receptors.\u003c\/p\u003e \u003cp\u003e3.2.2 Opsonisation.\u003c\/p\u003e \u003cp\u003e3.2.3 Ingestion.\u003c\/p\u003e \u003cp\u003e3.2.4 Digestion.\u003c\/p\u003e \u003cp\u003e3.2.5 The respiratory burst.\u003c\/p\u003e \u003cp\u003e3.2.6 Other antimicrobial activities of lysosomes.\u003c\/p\u003e \u003cp\u003eDefensins.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e3.3 Inflammation.\u003c\/p\u003e \u003cp\u003e3.3.1 Inflammatory mediators.\u003c\/p\u003e \u003cp\u003e3.3.2 Cellular responses in inflammation.\u003c\/p\u003e \u003cp\u003e3.3.3 Chemokines.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e3.4 Haemostasis and thrombosis.\u003c\/p\u003e \u003cp\u003e3.4.1 Regulation of coagulation.\u003c\/p\u003e \u003cp\u003e3.4.2 The fibrinolytic system.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 The adaptive immune response.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Antigen processing and presentation by MHC gene products.\u003c\/p\u003e \u003cp\u003e4.1.1 Generation of peptides presented by MHC Class I molecules.\u003c\/p\u003e \u003cp\u003eAssembly and intracellular transport of MHC Class I molecules.\u003c\/p\u003e \u003cp\u003e4.1.2 Generation of peptides presented by MHC Class II molecules.\u003c\/p\u003e \u003cp\u003eAssembly and intracellular transport of MHC Class II molecules.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.2 Antigen processing and presentation by CD1.\u003c\/p\u003e \u003cp\u003e4.2.1 Structure of CD1.\u003c\/p\u003e \u003cp\u003e4.2.2 Antigen presentation by CD1.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.3 Cell-mediated immunity.\u003c\/p\u003e \u003cp\u003e4.3.1 Antigen-specific T cell stimulation.\u003c\/p\u003e \u003cp\u003eT cell responses to antigen stimulation.\u003c\/p\u003e \u003cp\u003eTh\u003csub\u003e0\u003c\/sub\u003e, Th\u003csub\u003e1\u003c\/sub\u003e and Th\u003csub\u003e2\u003c\/sub\u003e cells.\u003c\/p\u003e \u003cp\u003e4.3.2 Other cells in cell-mediated immunity.\u003c\/p\u003e \u003cp\u003eMechanisms of target cell death.\u003c\/p\u003e \u003cp\u003eCytotoxic T cells.\u003c\/p\u003e \u003cp\u003eMacrophages.\u003c\/p\u003e \u003cp\u003eNK cells.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.4 Cell adaptive immunity.\u003c\/p\u003e \u003cp\u003e4.4.1 B cell differentiation and antibody production.\u003c\/p\u003e \u003cp\u003eClass switching.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.5 Lymphocyte memory.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.6 The mucosal immune response.\u003c\/p\u003e \u003cp\u003e4.6.1 Structure of the mucosal immune system.\u003c\/p\u003e \u003cp\u003eOrganised mucosal lymphoid tissue.\u003c\/p\u003e \u003cp\u003eIntraepithelial cells.\u003c\/p\u003e \u003cp\u003eLeukocytes in the lamina propria.\u003c\/p\u003e \u003cp\u003e4.6.2 Immunoglobulins and mucosal immunity.\u003c\/p\u003e \u003cp\u003eProduction of other immunoglobulins in the mucosa.\u003c\/p\u003e \u003cp\u003e4.6.3 The mucosae and their role in immunity.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.7 Tolerance.\u003c\/p\u003e \u003cp\u003e4.7.1 Lymphocyte tolerance.\u003c\/p\u003e \u003cp\u003eInduction time.\u003c\/p\u003e \u003cp\u003eAntigen dose.\u003c\/p\u003e \u003cp\u003eAntigen persistence.\u003c\/p\u003e \u003cp\u003eSpecificity.\u003c\/p\u003e \u003cp\u003eDuration.\u003c\/p\u003e \u003cp\u003eRoute of administration.\u003c\/p\u003e \u003cp\u003eTissue specificity.\u003c\/p\u003e \u003cp\u003e4.7.2 Mechanisms of tolerance induction.\u003c\/p\u003e \u003cp\u003eClonal deletion.\u003c\/p\u003e \u003cp\u003eClonal anergy.\u003c\/p\u003e \u003cp\u003eClonal exhaustion.\u003c\/p\u003e \u003cp\u003eClonal abortion.\u003c\/p\u003e \u003cp\u003eAntibody forming cell (AFC) blockade.\u003c\/p\u003e \u003cp\u003e4.7.3 Maintenance of tolerance.\u003c\/p\u003e \u003cp\u003eRegulatory T cells.\u003c\/p\u003e \u003cp\u003eAntibody-induced tolerance.\u003c\/p\u003e \u003cp\u003e4.7.4 Mechanisms involved in the development of incomplete tolerance.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Abnormalities of the immune system.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Hypersensitivity.\u003c\/p\u003e \u003cp\u003e5.1.1 Hypersensitivity reactions.\u003c\/p\u003e \u003cp\u003e5.1.2 Type I hypersensitivity.\u003c\/p\u003e \u003cp\u003eRegulation of Type I hypersensitivity.\u003c\/p\u003e \u003cp\u003eHumoral events in allergy.\u003c\/p\u003e \u003cp\u003e5.1.3 Type II hypersensitivity.\u003c\/p\u003e \u003cp\u003e5.1.4 Type III hypersensitivity.\u003c\/p\u003e \u003cp\u003e5.1.5 Type IV hypersensitivity.\u003c\/p\u003e \u003cp\u003eTuberculin-type DTH.\u003c\/p\u003e \u003cp\u003eGranuloma formation.\u003c\/p\u003e \u003cp\u003eContact hypersensitivity.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e5.2 Autoimmunity and autoimmune diseases.\u003c\/p\u003e \u003cp\u003e5.2.1 Causes of autoimmunity.\u003c\/p\u003e \u003cp\u003eGenetic factors in autoimmune disease.\u003c\/p\u003e \u003cp\u003eSex-linked factors in autoimmune disease.\u003c\/p\u003e \u003cp\u003eStress and neurochemicals in autoimmune disease.\u003c\/p\u003e \u003cp\u003eChemicals and pharmaceuticals in autoimmune disease.\u003c\/p\u003e \u003cp\u003eViruses in autoimmune disease.\u003c\/p\u003e \u003cp\u003eAntigen mimicry.\u003c\/p\u003e \u003cp\u003e5.2.2 Classification of autoimmune disease.\u003c\/p\u003e \u003cp\u003e5.2.3 Immunopathology of autoimmune diseases.\u003c\/p\u003e \u003cp\u003e5.2.4 The immunology of autoimmune disease.\u003c\/p\u003e \u003cp\u003eTarget antigens.\u003c\/p\u003e \u003cp\u003eNon-specific immunity in autoimmune disease.\u003c\/p\u003e \u003cp\u003eMononuclear phagocytes in non-specific immunity.\u003c\/p\u003e \u003cp\u003eMononuclear phagocytes in specific immunity.\u003c\/p\u003e \u003cp\u003eDendritic cells in autoimmune disease.\u003c\/p\u003e \u003cp\u003eRole of T cells in autoimmune disease.\u003c\/p\u003e \u003cp\u003eB cells in autoimmune disease.\u003c\/p\u003e \u003cp\u003eCytokine defects.\u003c\/p\u003e \u003cp\u003eChemokines in autoimmune disease.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e5.3 Immunodeficiency diseases.\u003c\/p\u003e \u003cp\u003e5.3.1 Classification of immunodeficiency diseases.\u003c\/p\u003e \u003cp\u003e5.3.2 Primary immunodeficiency diseases.\u003c\/p\u003e \u003cp\u003e5.3.3 B cell abnormalities.\u003c\/p\u003e \u003cp\u003eSelective immunoglobulin A deficiency.\u003c\/p\u003e \u003cp\u003eX-linked agammaglobulinaemia (XLA).\u003c\/p\u003e \u003cp\u003eCD40 ligand deficiency.\u003c\/p\u003e \u003cp\u003eX-linked lymphoproliferative disease (Duncan’s syndrome).\u003c\/p\u003e \u003cp\u003e5.3.4 T cell abnormalities.\u003c\/p\u003e \u003cp\u003eCongenital thymic aplasia (Di George syndrome).\u003c\/p\u003e \u003cp\u003eWiskott–Aldrich syndrome.\u003c\/p\u003e \u003cp\u003e5.3.5 T and B cell abnormalities.\u003c\/p\u003e \u003cp\u003eSevere combined immunodeficiency disease (SCID).\u003c\/p\u003e \u003cp\u003eX-linked severe combined immunodeficiency disease (XSCID).\u003c\/p\u003e \u003cp\u003eSCID with adenosine deaminase deficiency (ADA-SCID).\u003c\/p\u003e \u003cp\u003eThe bare lymphocyte syndrome.\u003c\/p\u003e \u003cp\u003e5.3.6 Abnormalities associated with phagocytic cells.\u003c\/p\u003e \u003cp\u003eChediak–Higashi syndrome (CHS).\u003c\/p\u003e \u003cp\u003eChronic granulomatous disease (CGD).\u003c\/p\u003e \u003cp\u003e5.3.7 Abnormalities of the complement pathway.\u003c\/p\u003e \u003cp\u003eDeficiencies of complement components.\u003c\/p\u003e \u003cp\u003eThe alternative pathway.\u003c\/p\u003e \u003cp\u003eThe classical pathway.\u003c\/p\u003e \u003cp\u003eC1INH deficiency – hereditary angioedema (HAE).\u003c\/p\u003e \u003cp\u003e5.3.8 Acquired immunodeficiencies.\u003c\/p\u003e \u003cp\u003eIatrogenic immunodeficiencies.\u003c\/p\u003e \u003cp\u003e5.3.9 The acquired immunodeficiency syndrome (AIDS).\u003c\/p\u003e \u003cp\u003eThe human immunodeficiency virus (HIV).\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Infection, immunity, immunopathogenesis.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 The innate immune system in infection.\u003c\/p\u003e \u003cp\u003e6.1.1 The skin.\u003c\/p\u003e \u003cp\u003e6.1.2 The mucosae.\u003c\/p\u003e \u003cp\u003e6.1.3 Protective chemicals.\u003c\/p\u003e \u003cp\u003eLysozyme.\u003c\/p\u003e \u003cp\u003eAlimentary fluids.\u003c\/p\u003e \u003cp\u003eComplement.\u003c\/p\u003e \u003cp\u003eDefensins.\u003c\/p\u003e \u003cp\u003eNatural antibodies.\u003c\/p\u003e \u003cp\u003e6.1.4 The role of normal body flora.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e6.2 Infection – the role of the innate immune system.\u003c\/p\u003e \u003cp\u003e6.2.1 Attachment.\u003c\/p\u003e \u003cp\u003e6.2.2 The body’s response to invasion – fever.\u003c\/p\u003e \u003cp\u003e6.2.3 Cells involved in innate immunity in infection.\u003c\/p\u003e \u003cp\u003ePhagocytic cells.\u003c\/p\u003e \u003cp\u003eNatural killer cells.\u003c\/p\u003e \u003cp\u003ePlatelets.\u003c\/p\u003e \u003cp\u003e6.2.4 Inflammation and immunopathology.\u003c\/p\u003e \u003cp\u003eEndotoxin.\u003c\/p\u003e \u003cp\u003eEndotoxin-induced injury.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e6.3 Infection – the role of the specific immune response.\u003c\/p\u003e \u003cp\u003e6.3.1 Intracellular pathogens and fungi.\u003c\/p\u003e \u003cp\u003e6.3.2 Parasitic infections.\u003c\/p\u003e \u003cp\u003e6.3.3 The role of antibody in immunity to infection.\u003c\/p\u003e \u003cp\u003eOpsonisation.\u003c\/p\u003e \u003cp\u003eComplement activation.\u003c\/p\u003e \u003cp\u003eInhibition of adherence.\u003c\/p\u003e \u003cp\u003eToxin neutralisation.\u003c\/p\u003e \u003cp\u003eVirus neutralisation.\u003c\/p\u003e \u003cp\u003eInhibition of microbial enzyme activity.\u003c\/p\u003e \u003cp\u003eInhibition of microbial growth.\u003c\/p\u003e \u003cp\u003e6.3.4 Pathology due to specific antibody.\u003c\/p\u003e \u003cp\u003ePolyclonal B cell activation.\u003c\/p\u003e \u003cp\u003eImmune complex formation.\u003c\/p\u003e \u003cp\u003e6.3.5 T cell-mediated immunity.\u003c\/p\u003e \u003cp\u003eParasitic infections.\u003c\/p\u003e \u003cp\u003eViral infections.\u003c\/p\u003e \u003cp\u003eTh\u003csub\u003e1\u003c\/sub\u003e and Th\u003csub\u003e2\u003c\/sub\u003e cells.\u003c\/p\u003e \u003cp\u003eCytotoxic T cell activity.\u003c\/p\u003e \u003cp\u003eCytolytic mechanisms.\u003c\/p\u003e \u003cp\u003e6.3.6 Pathology caused by the cell-mediated immune response.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e6.4 Cytokines in immunity to infection.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Immunity and the MHC.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Transplantation.\u003c\/p\u003e \u003cp\u003e7.1.1 Tissue typing.\u003c\/p\u003e \u003cp\u003e7.1.2 Cross-matching.\u003c\/p\u003e \u003cp\u003e7.1.3 Rejection.\u003c\/p\u003e \u003cp\u003eDirect allorecognition.\u003c\/p\u003e \u003cp\u003eIndirect allorecognition.\u003c\/p\u003e \u003cp\u003eMechanisms involved in hyperacute rejection.\u003c\/p\u003e \u003cp\u003eMechanisms involved in acute rejection.\u003c\/p\u003e \u003cp\u003eMechanisms involved in chronic rejection.\u003c\/p\u003e \u003cp\u003eThe role of the graft endothelium in rejection.\u003c\/p\u003e \u003cp\u003e7.1.4 Kidney transplantation.\u003c\/p\u003e \u003cp\u003ePre-sensitisation.\u003c\/p\u003e \u003cp\u003eCadaveric kidney transplantation.\u003c\/p\u003e \u003cp\u003e7.1.5 Liver transplantation.\u003c\/p\u003e \u003cp\u003eProcedure.\u003c\/p\u003e \u003cp\u003ePrimary non-function and rejection.\u003c\/p\u003e \u003cp\u003e7.1.6 Heart transplantation.\u003c\/p\u003e \u003cp\u003eRejection.\u003c\/p\u003e \u003cp\u003e7.1.7 Bone marrow transplantation.\u003c\/p\u003e \u003cp\u003e7.1.8 Pancreas transplantation.\u003c\/p\u003e \u003cp\u003e7.1.9 Xenotransplantation.\u003c\/p\u003e \u003cp\u003eChoice of donor.\u003c\/p\u003e \u003cp\u003eBarriers to xenotransplantation.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e7.2 The immunology of reproduction.\u003c\/p\u003e \u003cp\u003e7.2.1 The development of maternal and foetal tissues.\u003c\/p\u003e \u003cp\u003e7.2.2 Female reproductive immunology.\u003c\/p\u003e \u003cp\u003e7.2.3 Maternal–foetal exchange.\u003c\/p\u003e \u003cp\u003e7.2.4 Effect of pregnancy on the maternal immune response.\u003c\/p\u003e \u003cp\u003ePeripheral immunity.\u003c\/p\u003e \u003cp\u003eFoetal–uterine immunity.\u003c\/p\u003e \u003cp\u003e7.2.5 Cytokine–endocrine relationship in pregnancy.\u003c\/p\u003e \u003cp\u003eOestrogen and progesterone.\u003c\/p\u003e \u003cp\u003eHuman chorionic gonadotrophin.\u003c\/p\u003e \u003cp\u003e7.2.6 Immunity to infection in pregnancy.\u003c\/p\u003e \u003cp\u003e7.2.7 Immunocompetent cells in the decidua.\u003c\/p\u003e \u003cp\u003eLarge granular lymphocytes.\u003c\/p\u003e \u003cp\u003eMacrophages.\u003c\/p\u003e \u003cp\u003eDecidual antigen presenting cells.\u003c\/p\u003e \u003cp\u003eT lymphocytes.\u003c\/p\u003e \u003cp\u003e7.2.8 Recurrent, spontaneous, abortion\u003c\/p\u003e \u003cp\u003e7.2.9 The immunology of male reproduction.\u003c\/p\u003e \u003cp\u003eThe blood–testis barrier.\u003c\/p\u003e \u003cp\u003eSperm-specific antigens.\u003c\/p\u003e \u003cp\u003eImmunologically active cells in semen.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Other diseases.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Atherosclerosis.\u003c\/p\u003e \u003cp\u003e8.1.1 Normal arterial wall.\u003c\/p\u003e \u003cp\u003e8.1.2 Extracellular matrix.\u003c\/p\u003e \u003cp\u003e8.1.3 Pathogenesis of atherosclerosis.\u003c\/p\u003e \u003cp\u003eRole of lipoproteins in atherosclerosis.\u003c\/p\u003e \u003cp\u003e8.1.4 Plaque development.\u003c\/p\u003e \u003cp\u003e8.1.5 Mononuclear cells in atherosclerosis – macrophages and dendritic cells.\u003c\/p\u003e \u003cp\u003e8.1.6 Mononuclear cells in atherosclerosis – T cells.\u003c\/p\u003e \u003cp\u003e8.1.7 Mononuclear cells in atherosclerosis – B cells.\u003c\/p\u003e \u003cp\u003e8.1.8 Other immune cells in atherosclerotic plaques.\u003c\/p\u003e \u003cp\u003e8.1.9 Cytokines in atherosclerosis.\u003c\/p\u003e \u003cp\u003e8.1.10 Is atherosclerosis an autoimmune disease?\u003c\/p\u003e \u003cp\u003ePotential autoantigens.\u003c\/p\u003e \u003cp\u003e8.1.11 Infection and atherosclerosis.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e8.2 Tumour immunology.\u003c\/p\u003e \u003cp\u003e8.2.1 The nature of malignant disease.\u003c\/p\u003e \u003cp\u003e8.2.2 Causes of malignancy.\u003c\/p\u003e \u003cp\u003ePhysical carcinogens.\u003c\/p\u003e \u003cp\u003eChemical carcinogens.\u003c\/p\u003e \u003cp\u003eViral carcinogens.\u003c\/p\u003e \u003cp\u003eOncogenes.\u003c\/p\u003e \u003cp\u003e8.2.3 Tumour antigens.\u003c\/p\u003e \u003cp\u003eMelanoma–melanocyte differentiation antigens (MMDAs).\u003c\/p\u003e \u003cp\u003eCancer testes antigens (CTAs).\u003c\/p\u003e \u003cp\u003eRenal carcinoma antigen.\u003c\/p\u003e \u003cp\u003eNon-mutated shared antigens.\u003c\/p\u003e \u003cp\u003eMutated antigens.\u003c\/p\u003e \u003cp\u003e8.2.4 Tumour suppressor gene – oncogene networks.\u003c\/p\u003e \u003cp\u003e8.2.5 Tumour immunology.\u003c\/p\u003e \u003cp\u003eInnate immunity.\u003c\/p\u003e \u003cp\u003eInflammation and the development of cancer.\u003c\/p\u003e \u003cp\u003eSpecific immunity.\u003c\/p\u003e \u003cp\u003eTumour cell evasion of the immune response.\u003c\/p\u003e \u003cp\u003e8.2.6 Cancer biotherapy.\u003c\/p\u003e \u003cp\u003eAnti-tumour vaccines.\u003c\/p\u003e \u003cp\u003eAnti-idiotypic antibodies.\u003c\/p\u003e \u003cp\u003eBiological response modifiers (BRM).\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAnswers to \"now test yourself!\"\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Biology, life sciences [\u003ca title=\"See our other books on Biology, life sciences\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Biology,%20life%20sciences%20%5BPS%5D%22\"\u003ePS\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Interscience","offers":[{"title":"Brand New","offer_id":52511407079704,"sku":"9780470845240","price":59.19,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470845240.jpg?v=1786599530","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/immunology-for-life-scientists-paperback-softback-9780470845240","provider":"Freshly Printed Books","version":"1.0","type":"link"}